Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is focusing on innovative drug development and is expected to see a recovery in domestic sales, with a projected increase in revenue from its oncology/immunology business in 2026 [4][10] - The company achieved a total revenue of $549 million in 2025, a decrease of 12.96% year-on-year, but expects a rebound in 2026 with projected revenue of $655 million [5][6] - The overseas sales of the company's core product, FRUZAQLA, showed a robust growth of 26% year-on-year, contributing to a total market sales of $5.2 billion for oncology products, which is a 5% increase [7][8] Financial Performance - In 2025, the company reported a net profit of $457 million, a significant increase from $40 million in 2024, largely due to the sale of non-core business assets [8] - The company anticipates a net profit of $57 million in 2026, with earnings per share (EPS) projected to be $0.07, and expected to grow to $0.10 by 2028 [5][10] - The gross margin is expected to improve from 38.68% in 2025 to 48.56% by 2028, indicating better cost management and product pricing strategies [5][10] Product Pipeline and Clinical Development - The company has a rich pipeline of late-stage clinical candidates, including SAFFRON and SANOVO studies for its products, which are expected to yield results in 2026 and 2027 [8][9] - The ATTC platform is showing potential clinical value and is expected to drive long-term growth, with several candidates entering clinical trials [8][9] - The company is also advancing its other clinical candidates, including HMPL-306 and HMPL-A251, which are in various stages of development [9]
和黄医药（00013）：呋喹替尼海外销售环比增长，ATTC平台有望打开公司增长空间